ISOPTO CETAMIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ISOPTO CETAMIDE (ISOPTO CETAMIDE).
Sulfacetamide inhibits bacterial dihydropteroate synthase, disrupting folic acid synthesis and thereby inhibiting bacterial growth.
| Metabolism | Sulfacetamide is primarily metabolized in the liver via acetylation (N-acetyltransferase), and also undergoes glucuronidation and oxidation. |
| Excretion | Primarily renal (sodium sulfacetamide excreted unchanged in urine, ~85% within 24 hours). Minor biliary/fecal elimination. |
| Half-life | Terminal elimination half-life of sodium sulfacetamide is 7-12 hours in normal renal function; prolonged in renal impairment. |
| Protein binding | Approximately 50-70% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd ~0.3-0.5 L/kg, indicating moderate tissue penetration consistent with sulfonamide distribution. |
| Bioavailability | Ophthalmic: systemic absorption minimal (<10%) after topical administration; oral bioavailability of sulfacetamide is nearly 100% but not relevant for ophthalmic formulation. |
| Onset of Action | Ophthalmic: therapeutic effect within 1-2 hours after instillation for conjunctival bacterial infections. |
| Duration of Action | Ophthalmic: bacteriostatic concentrations maintained for 4-6 hours; requires frequent dosing (every 2-3 hours during waking hours). |
1-2 drops into conjunctival sac every 2-3 hours initially, then taper as infection resolves. Ophthalmic suspension (10% or 30%).
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No systemic absorption; no adjustment required. |
| Liver impairment | Not metabolized hepatically; no adjustment required. |
| Pediatric use | 1 drop into affected eye(s) every 2-3 hours initially, then reduce frequency based on response. Weight-based dosing not applicable; use same concentration as adults. |
| Geriatric use | No specific dose adjustment; monitor for local irritation and consider lower concentration (10%) if dry eye or reduced tear production. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ISOPTO CETAMIDE (ISOPTO CETAMIDE).
| Breastfeeding | Sulfacetamide is excreted into breast milk in small amounts. The M/P ratio is not well defined but likely <1, corresponding to low infant exposure. However, sulfonamides may cause hemolytic anemia or kernicterus in nursing infants, particularly if premature, glucose-6-phosphate dehydrogenase deficient, or hyperbilirubinemic. Caution is advised; consider alternative therapy during breastfeeding, especially in high-risk infants. |
| Teratogenic Risk | Isopto Cetamide (sulfacetamide sodium) is a sulfonamide antimicrobial. Sulfonamides are associated with an increased risk of kernicterus and hemolytic anemia in the fetus, particularly when administered near term. First trimester exposure may be associated with a small risk of congenital malformations, but data are limited. Second and third trimester use, especially in the last month, carries risk of neonatal jaundice and kernicterus due to bilirubin displacement from albumin. Avoid use after 36 weeks gestation or in labor. |
■ FDA Black Box Warning
None.
| Common Effects | Dry skin Increased liver enzymes Rash |
| Serious Effects |
Hypersensitivity to sulfacetamide or any component of the formulation, sulfonamides, or sulfites.
| Precautions | Hypersensitivity reactions may occur; cross-sensitivity with other sulfonamides is possible. Prolonged use may lead to overgrowth of nonsusceptible organisms including fungi. Discontinue if signs of local irritation or hypersensitivity develop. Patients with dry eye syndrome may experience increased irritation. |
Loading safety data…
| Fetal Monitoring | Monitor maternal renal and hepatic function and complete blood cell count, especially with prolonged therapy. In the third trimester, assess fetal bilirubin levels if maternal administration is necessary. Observe neonates for signs of jaundice, hemolysis, or kernicterus if exposed near term. |
| Fertility Effects | No specific studies on effects of sulfacetamide on fertility. Sulfonamides have not been reported to impair fertility in humans; however, animal studies at high doses have shown some effects on spermatogenesis and ovarian function. Clinical relevance is uncertain. |